ATE321565T1 - Behandlung von osteoporose - Google Patents

Behandlung von osteoporose

Info

Publication number
ATE321565T1
ATE321565T1 AT99923352T AT99923352T ATE321565T1 AT E321565 T1 ATE321565 T1 AT E321565T1 AT 99923352 T AT99923352 T AT 99923352T AT 99923352 T AT99923352 T AT 99923352T AT E321565 T1 ATE321565 T1 AT E321565T1
Authority
AT
Austria
Prior art keywords
bone
receptor
cell surface
formation
condition
Prior art date
Application number
AT99923352T
Other languages
English (en)
Inventor
Stephen Shaughnessy
Richard Carl Austin
Original Assignee
Hamilton Civic Hospitals Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hamilton Civic Hospitals Res filed Critical Hamilton Civic Hospitals Res
Application granted granted Critical
Publication of ATE321565T1 publication Critical patent/ATE321565T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5431—IL-11
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
AT99923352T 1998-05-19 1999-05-19 Behandlung von osteoporose ATE321565T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002237915A CA2237915A1 (en) 1998-05-19 1998-05-19 Osteoporosis treatment

Publications (1)

Publication Number Publication Date
ATE321565T1 true ATE321565T1 (de) 2006-04-15

Family

ID=4162449

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99923352T ATE321565T1 (de) 1998-05-19 1999-05-19 Behandlung von osteoporose

Country Status (8)

Country Link
US (3) US6998123B1 (de)
EP (2) EP1674108A3 (de)
JP (1) JP2002515444A (de)
AT (1) ATE321565T1 (de)
AU (1) AU767749B2 (de)
CA (1) CA2237915A1 (de)
DE (1) DE69930622D1 (de)
WO (1) WO1999059608A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2237915A1 (en) 1998-05-19 1999-11-19 Stephen Shaughnessy Osteoporosis treatment
WO2003099322A2 (en) * 2002-05-24 2003-12-04 Isis Innovation Limited Il-11 derivatives and therapeutic uses thereof
WO2005065418A2 (en) * 2003-12-31 2005-07-21 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy
US8518888B2 (en) * 2008-10-14 2013-08-27 Csl Limited Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R
WO2011154413A1 (en) 2010-06-07 2011-12-15 Fritz-Lipmann-Insitut E. V. Leibniz-Institut Für Altersforschung Agent against glucocorticoid-induced osteoporosis
CN117843785A (zh) * 2013-02-07 2024-04-09 Csl有限公司 Il-11r结合蛋白及其应用
JP6959274B2 (ja) * 2013-02-07 2021-11-02 シーエスエル、リミテッド Ｉｌ−１１ｒ結合タンパク質及びその使用
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
GB201621439D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
US20180186871A1 (en) * 2016-12-16 2018-07-05 Singapore Health Services Pte Ltd. Il-11 antibodies
EP3914621A1 (de) 2019-01-21 2021-12-01 Singapore Health Services Pte. Ltd. Behandlung von hepatotoxizität
GB201902419D0 (en) 2019-02-22 2019-04-10 Singapore Health Serv Pte Ltd Treatment of kidney injury
BR112021021921A2 (pt) 2019-05-03 2021-12-28 Nat Univ Singapore Agente, uso de um agente e método de tratamento ou prevenção de uma doença metabólica
GB201906291D0 (en) 2019-05-03 2019-06-19 Singapore Health Serv Pte Ltd Treatment and prevention of metabolic diseases
GB202009292D0 (en) 2020-06-18 2020-08-05 Singapore Health Serv Pte Ltd Treatment and prevention of disease caused by type IV collagen dysfunction
GB202017244D0 (en) 2020-10-30 2020-12-16 Nat Univ Singapore Methods to extend health-span and treat age-related diseases
JP2024512279A (ja) 2021-02-26 2024-03-19 バイエル アクチェンゲゼルシャフト 異常子宮出血の処置における使用のためのｉｌ－１１又はｉｌ－１１ｒａの阻害剤
WO2023006765A1 (en) 2021-07-26 2023-02-02 Boehringer Ingelheim International Gmbh Treatment and prevention of alcoholic liver disease
US20250082608A1 (en) 2021-12-16 2025-03-13 Singapore Health Services Pte Ltd. Treatment and prevention of glomerular disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5215895A (en) * 1989-11-22 1993-06-01 Genetics Institute, Inc. Dna encoding a mammalian cytokine, interleukin-11
US5270181A (en) 1991-02-06 1993-12-14 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
US5292646A (en) 1991-02-06 1994-03-08 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
US5888510A (en) * 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
IT1274350B (it) 1994-12-06 1997-07-17 Angeletti P Ist Richerche Bio Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130
IT1274782B (it) * 1994-12-14 1997-07-24 Angeletti P Ist Richerche Bio Metodo per selezionare superagonisti, antagonisti e superantagonisti di ormoni del cui complesso recettoriale fa parte gp 130
EP1566440A3 (de) * 1994-12-22 2005-10-19 Genetics Institute, Inc. Menschlicher Interleukin-11 Rezeptor
GB9621095D0 (en) * 1996-10-09 1996-11-27 Imperial College Novel system
CA2237915A1 (en) 1998-05-19 1999-11-19 Stephen Shaughnessy Osteoporosis treatment
ES2279809T3 (es) * 2000-04-05 2007-09-01 Zymogenetics, Inc. Receptores de citoquina zalfa11 solubles.

Also Published As

Publication number Publication date
WO1999059608A3 (en) 2000-04-06
EP1079847B1 (de) 2006-03-29
EP1674108A2 (de) 2006-06-28
EP1079847A2 (de) 2001-03-07
WO1999059608A2 (en) 1999-11-25
US6998123B1 (en) 2006-02-14
CA2237915A1 (en) 1999-11-19
JP2002515444A (ja) 2002-05-28
EP1674108A3 (de) 2006-08-02
DE69930622D1 (de) 2006-05-18
AU767749B2 (en) 2003-11-20
US6846907B1 (en) 2005-01-25
AU4027799A (en) 1999-12-06
US20040142871A1 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
ATE321565T1 (de) Behandlung von osteoporose
RU2002124123A (ru) Модифицированный фактор viii
NO913211L (no) Nytt monoklonalt antistoff mot nytt antigen knyttet til menneske-tumorer.
BR0011103A (pt) Composição farmacêutica, e, métodos para prevenção ou tratamento de um distúrbio caracterizado por deposição amilóide em um sujeito mamìfero, para determinar o prognóstico de um paciente que está sendo submetido a tratamento de um distúrbio amilóide e para prevenção ou tratamento de uma doença caracterizada por um depósito amilóide em um paciente
DK0592521T3 (da) Marv-afledte humane mesenchymal-stamceller og monoklonale antistoffer specifikke for nævnte celler
ATE403680T1 (de) Herstellung tetravalenter antikörper
EP0815125A4 (de) gC1q-REZEPTOR, DARAN BINDENDE HIV-1 gp120-REGION, VERWANDTE PEPTIDE UND ANTIKÖRPER
FI963805A0 (fi) Hermotukisoluista peräisin olevaa neurotrofista tekijää (GDNF) koodaavat yhdistelmä-DNA-tekniset adenovirukset
BG101392A (en) Method of treating diabetes mellitus using kgf
Castronovo et al. Identification of a 14-kDa laminin binding protein (HLBP14) in human melanoma cells that is identical to the 14-kDa galactoside binding lectin
ATE265226T1 (de) Verwendung von wolinella succinogenes asparaginase zur behandlung von asparagin- abhängiger krankheiten
ATE349523T1 (de) Verfahren zur verwendung eines humanen il-17 verwandten polypeptids zur behandlung von krankheiten
IL145310A0 (en) Vascular adhesion molecules and modulation of their function
ATE321856T1 (de) Humane rezeptortyrosinkinase
ATE259652T1 (de) Neuronale verwendungen des bmp-11
WO2003040296A3 (en) Men protein, gst2, rab-rp1, csp, f-box protein lilina/fbl7, abc50, coronin, sec61 alpha, or vhappa1-1, or homologous proteins involved in the regulation of energy homeostasis
Hanauske et al. Human colon cancer cell lines secrete alpha TGF-like activity
PL338649A1 (en) Lactoferrin bonding neisseria protein
DE69728654D1 (de) Verwendung von il-7 zur behandlung von autoimmunkrankheiten, insbesondere insulinabhängigem diabetes mellitus
DE69634994D1 (de) Bindegewebe-wachstumsfaktor 3.
WO2000038706A3 (en) Methods for treating cancer and for mediating chemotaxis of dendritic cells
ATE363072T1 (de) Monoklonaler antikörper gegen mxa und mxb
NO20015751D0 (no) Nevrotrofiske faktorer i behandlingen av perifer nervedysfunksjon i bekkenområdet
Asokan et al. Neoplastic association of enhanced type V collagen production in rat fibrosarcoma
Mardon et al. A tissue‐specific protein in rat osteogenic tissues

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties